Glenmark Pharmaceuticals Limited
GLENMARK · 532296 · Healthcare · Pharmaceuticals
- Market cap
- Rs 66,007 Cr
- P/E
- 36.71x
- P/B
- 6.28x
- 52W high / low
- Rs 2,537.6 / Rs 1,798.6
Our computed roe (15.46%) diverges from BSE's own published figure (-0.84%) by more than 100%. BSE's figure is a different, BSE-computed number (not necessarily TTM, standalone-only) — treat as a cross-check/fallback signal, not proof either figure is wrong. Our computed operating_margin (15.43%) diverges from BSE's own published figure (-1.37%) by more than 100%. BSE's figure is a different, BSE-computed number (not necessarily TTM, standalone-only) — treat as a cross-check/fallback signal, not proof either figure is wrong. Our computed net_margin (10.14%) diverges from BSE's own published figure (-3.44%) by more than 100%. BSE's figure is a different, BSE-computed number (not necessarily TTM, standalone-only) — treat as a cross-check/fallback signal, not proof either figure is wrong.
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Limited is listed on the NSE under the symbol GLENMARK and on the BSE under scrip code 532296. It is classified in the Healthcare sector, industry: Pharmaceuticals. It is a constituent of BSE 500, NIFTY 200, NIFTY 500, NIFTY Midcap 150 and NIFTY Pharma. The company listed on 7 Feb 2000 and has a face value of Rs 1.
The latest available end-of-day price is Rs 2,339 (+1.70% on the day), for a market capitalisation of Rs 66,007 Cr. Trailing P/E is 36.71x and price-to-book is 6.28x. The 52-week range is Rs 1,798.6 to Rs 2,537.6. The latest price is 73% of the way from the 52-week low to the 52-week high.
Against the 15-company comparison set from the official BSE basic industry Pharmaceuticals, its market capitalisation is 0.6 times the peer median of Rs 1,09,706 Cr, and its P/E of 36.71x compares with a peer median of 36.40x. The comparison set is chosen mechanically from the exchange classification; it is not a ranking.
Latest annual results
For FY26 (year ended 31 Mar 2026), Glenmark Pharmaceuticals Limited reported revenue of Rs 16,983 Cr and net profit of Rs 1,362 Cr, with a net margin of 8.02% and earnings per share of Rs 48.26 (consolidated statements).
Year-on-year change: revenue +29.83%; net profit +30.06%; EPS +30.05%. Three-year compound annual growth rate: revenue +9.44%; net profit +53.37%.
At the same date the balance sheet shows total assets of Rs 19,908 Cr, shareholders' equity of Rs 10,512 Cr, total debt of Rs 0 Cr, cash of Rs 1,175 Cr, a debt-to-equity ratio of 0.00 and operating cash flow of Rs 3,445 Cr.
On a trailing-twelve-month basis the filings add up to revenue of Rs 17,737 Cr, net income of Rs 1,798 Cr and a net margin of 10.14%.
Shareholding pattern
In the shareholding pattern for 30 Sept 2026, Glenmark Pharmaceuticals Limited's ownership is split: promoters 46.65%; foreign institutional investors (FIIs) 21.51%; domestic institutional investors (DIIs) 17.64%; retail and other shareholders 14.20%.
Compared with the filing for 30 Jun 2026: promoter holding 0.00 percentage points; FII holding +0.62 percentage points; DII holding −0.96 percentage points.
The same filing lists reported promoter pledge of 0.00% and 2,08,414 shareholders on record.
Recent filings and corporate actions
102 BSE corporate announcements were filed by Glenmark Pharmaceuticals Limited in the past twelve months; the most frequent category is "Company Update" (79). The most recent is "Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Intimation of Earnings Call" (Company Update), filed on 23 Oct 2026.
The disclosed corporate-action timeline lists 6 entries: dividend (6). The latest is a dividend (Final Dividend - Rs. - 2.5000) with ex-date 31 Aug 2026.
Figures are raw disclosures from official NSE/BSE and SEBI filings plus mechanically computed ratios, restated in words. This is research data, not investment advice, a rating or a recommendation; DalalOS is not a SEBI-registered investment advisor.
More
Peer comparison
Official BSE basic industry: Pharmaceuticals. Limited to companies within a 0.1x–10x market-cap band.
Edit columns
| Sun Pharmaceutical Industries Limited | Rs 1,761 | Rs 4,22,517 Cr | Rs 62,141 Cr | Rs 12,117 Cr | 34.94x | 15.53% |
| Divi's Laboratories Limited | Rs 9,664 | Rs 2,56,096 Cr | Rs 11,682 Cr | Rs 2,925 Cr | 87.69x | 18.44% |
| Torrent Pharmaceuticals Limited | Rs 4,580 | Rs 1,55,015 Cr | Rs 15,654 Cr | Rs 2,156 Cr | 73.16x | 27.30% |
| Laurus Labs Limited | Rs 2,244 | Rs 1,21,232 Cr | Rs 7,323 Cr | Rs 1,091 Cr | — | 22.38% |
| Zydus Lifesciences Limited | Rs 1,184.4 | Rs 1,18,203 Cr | Rs 29,052 Cr | Rs 4,593 Cr | 26.40x | 17.68% |
| Dr. Reddy's Laboratories Limited | Rs 1,345 | Rs 1,12,308 Cr | Rs 34,353 Cr | Rs 2,760 Cr | 40.02x | 7.84% |
| Cipla Limited | Rs 1,358 | Rs 1,09,706 Cr | Rs 28,855 Cr | Rs 2,854 Cr | 37.86x | 8.83% |
| Mankind Pharma Limited | Rs 2,469.3 | Rs 1,01,982 Cr | Rs 15,705 Cr | Rs 2,264 Cr | 45.45x | 14.78% |
| Aurobindo Pharma Limited | Rs 1,659.9 | Rs 95,511 Cr | Rs 35,625 Cr | Rs 3,711 Cr | 25.94x | 10.53% |
| Lupin Limited | Rs 1,989.9 | Rs 90,988 Cr | Rs 30,442 Cr | Rs 5,551 Cr | 16.44x | 27.89% |
| Glenmark Pharmaceuticals LimitedThis company | Rs 2,339 | Rs 66,007 Cr | Rs 18,236 Cr | Rs 1,798 Cr | 36.71x | 15.46% |
| Alkem Laboratories Limited | Rs 5,079 | Rs 60,719 Cr | Rs 15,681 Cr | Rs 2,204 Cr | 28.15x | 16.72% |
| Biocon Limited | Rs 351.9 | Rs 57,346 Cr | Rs 17,638 Cr | Rs 416 Cr | — | 1.78% |
| Abbott India Limited | Rs 26,145 | Rs 55,558 Cr | Rs 7,295 Cr | Rs 1,615 Cr | 34.41x | 35.85% |
| Gland Pharma Limited | Rs 3,074.5 | Rs 50,717 Cr | Rs 7,045 Cr | Rs 1,129 Cr | 44.88x | 11.57% |
| Median | Rs 2,244 | Rs 1,09,706 Cr | Rs 15,705 Cr | Rs 2,760 Cr | 36.40x | 16.72% |
Peers are selected mechanically from the official BSE industry hierarchy and current market-cap band. This is a comparison set, not a ranking or recommendation.
Companies related to Glenmark Pharmaceuticals
Same official industry (Pharmaceuticals)
- Sun Pharmaceutical Industries LimitedSUNPHARMA · Market cap Rs 4,22,517 Cr
- Divi's Laboratories LimitedDIVISLAB · Market cap Rs 2,56,096 Cr
- Torrent Pharmaceuticals LimitedTORNTPHARM · Market cap Rs 1,55,015 Cr
- Laurus Labs LimitedLAURUSLABS · Market cap Rs 1,21,232 Cr
- Zydus Lifesciences LimitedZYDUSLIFE · Market cap Rs 1,18,203 Cr
- Dr. Reddy's Laboratories LimitedDRREDDY · Market cap Rs 1,12,308 Cr
- Cipla LimitedCIPLA · Market cap Rs 1,09,706 Cr
- Mankind Pharma LimitedMANKIND · Market cap Rs 1,01,982 Cr
Other Healthcare companies of a similar market capitalisation
- Lupin LimitedLUPIN · Market cap Rs 90,988 Cr
- Max Healthcare Institute LimitedMAXHEALTH · Market cap Rs 82,837 Cr
- Alkem Laboratories LimitedALKEM · Market cap Rs 60,719 Cr
- Biocon LimitedBIOCON · Market cap Rs 57,346 Cr
- Fortis Healthcare LimitedFORTIS · Market cap Rs 56,992 Cr
- Abbott India LimitedABBOTINDIA · Market cap Rs 55,558 Cr
- Gland Pharma LimitedGLAND · Market cap Rs 50,717 Cr
- IPCA Laboratories LimitedIPCALAB · Market cap Rs 48,868 Cr
Companies are grouped mechanically from the exchange classification and listed by market capitalisation. This is a comparison set, not a ranking or recommendation.